NCI-2020-00751

A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

The ALCHEMIST trial focuses on adding immunotherapy to the treatment plan for non-small cell lung cancer (NSCLC) patients who have had surgery to remove their tumors. This trial, known as "Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO," aims to see if combining immunotherapy with standard chemotherapy after surgery is more effective than the usual treatment. Researchers also want to identify any markers in patients' bodies that could predict how well they respond to immunotherapy. Ultimately, the trial aims to improve treatment strategies for NSCLC patients after surgery by better understanding the role of immunotherapy.

Immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

Adjuvant Therapy: Therapy given after surgery for cancer

Resected: Some patients have a tumor that is “resectable,” which means that it is able to be removed with surgery.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04267848

Clinical Trial Site: Einstein

To see all available clinical trials click here.